secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105032
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test
--------------------------------------------------------------------------------

- Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.
- Net loss $9.4M ($0.10 per share) vs $17.0M loss a year ago; adjusted net loss $7.5M vs income $0.2M.
- FY2025 guidance: revenue $480-510M (flat to +6%); adjusted EBITDA $31.1-61.9M.
- Fourth Amendment to Credit Agreement waives Q2 2025 covenant test; must reset covenants by Sept 30, 2025; no additional borrowing until then.
- Cash and restricted cash $73.7M, no debt; expects cash plus product sales to fund ops for 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017025105032/0000950170-25-105032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017025105032/orgo-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer